Eloxx Pharmaceuticals stock reports an Alport trial milestone
Published on 09/29/2026 at 16:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eloxx Pharmaceuticals stock is tied to a clinical milestone after the company dosed the first two patients in its Phase 2b EXACT study on September 11, 2026. The trial is testing exaluren in nonsense mutation Alport syndrome, a rare kidney disease with no FDA-approved treatment aimed at its underlying genetic cause.
EXACT study sets the next test
According to PRNewswire on September 11, 2026, the randomized study is designed to enroll 24 patients. Its initial portion runs for 16 weeks with a placebo-controlled design, while topline data are expected in mid-2027 and the final readout is expected by the end of 2027.
The timing makes the trial the central operating checkpoint for Eloxx. The lead program is still clinical-stage, so the next material valuation test is the quality and timing of trial data rather than product revenue.
Cash position changed in Q2
Eloxx reported USD 61.96 million in cash and cash equivalents and USD 0 in total debt for the quarter ended June 30, 2026. The balance sheet therefore differs sharply from the USD 6.36 million cash position and USD 0 debt reported for March 31, 2026, giving the company USD 55.60 million more cash quarter over quarter.
Trefis reported that the June financing generated USD 66.0 million in gross proceeds and helped extend the operational runway into mid-2028. The latest quarter still showed a net loss of USD 4.50 million, or adjusted EPS of minus USD 0.66, according to MarketBeat in its August 11, 2026 earnings coverage.
ELOX trades below its yearly high
ELOX was trading at USD 15.42 on Nasdaq on September 29, 2026 at 10:49 a.m. ET. Its market capitalization was USD 53.0 million, while the 52-week range stood at USD 8.20 to USD 23.40.
The current quote is USD 7.98 below the 52-week high and USD 7.22 above the low. For investors, the next dated checkpoint is the mid-2027 readout from the EXACT study, while the cash balance provides a measurable counterweight to the continuing quarterly loss.
Eloxx Pharmaceuticals stock facts
- Company: Eloxx Pharmaceuticals, Inc.
- Ticker: ELOX
- Primary exchange: Nasdaq
- Nasdaq quote as of September 29, 2026 at 10:49 a.m. ET: USD 15.42
- Market capitalization: USD 53.0 million as of September 29, 2026
- 52-week range: USD 8.20-USD 23.40 as of September 29, 2026
- Sector / Industry: Healthcare / Biotechnology
